Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Fineline Cube Dec 29, 2025
Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Fineline Cube Dec 29, 2025
Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Fineline Cube Dec 29, 2025
Company Deals

TJ Biopharma Partners with Zhejiang Lab to Develop AI‑Driven Ultra‑Long‑Acting Growth Hormone

Fineline Cube Dec 29, 2025
Company Deals

HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology

Fineline Cube Dec 29, 2025
Policy / Regulatory

NMPA Releases 2025 Priority Approval Directory for Eight High-End Medical Device Categories

Fineline Cube Dec 29, 2025
Company Drug

Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China

Fineline Cube Dec 29, 2025
Company Drug

BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL

Fineline Cube Dec 29, 2025
Policy / Regulatory

China Introduces Trial Measures for Science and Technology Ethics Review

Fineline Cube Oct 13, 2023

The National Health Commission, Ministry of Science and Technology, Ministry of Education, and eight other...

Company Drug

Roche’s Ocrevus Demonstrates Long-Term Efficacy in Multiple Sclerosis Treatment

Fineline Cube Oct 13, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) has presented compelling long-term efficacy data for its selective...

Policy / Regulatory

China Releases First Supplement to 2020 Pharmacopoeia with 47 New Drug Varieties

Fineline Cube Oct 13, 2023

The National Medical Products Administration (NMPA) and the National Health Commission have announced the release...

Company Drug

Sichuan Huiyu Pharmaceutical’s HYP2090PTSA Gains NMPA Approval for KRAS G12C Solid Tumors

Fineline Cube Oct 13, 2023

Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a China-based pharmaceutical company, has announced that it...

Company Deals

Livzon Pharmaceutical Secures Licensing Agreement for LanssonPharm’s PDE4 Inhibitor in China

Fineline Cube Oct 13, 2023

China-based Livzon Pharmaceutical Group Inc., (HKG: 1513, SHE: 000513) has announced a significant licensing agreement...

Company Drug

AbbVie’s Rinvoq Demonstrates Sustained Efficacy in Late-Stage Atopic Dermatitis Study

Fineline Cube Oct 13, 2023

AbbVie (NYSE: ABBV) has announced late-stage results for its JAK inhibitor Rinvoq (upadacitinib) in the...

Policy / Regulatory

China’s Healthcare Landscape: Key Insights from the 2022 Statistical Communique

Fineline Cube Oct 13, 2023

The National Health Commission (NHC) has released “China’s Healthcare Statistical Communique 2022,” providing a comprehensive...

Company Drug

Lee’s Pharmaceutical’s Subsidiary Announces Positive Results for Myopia Treatment NVK002

Fineline Cube Oct 13, 2023

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), through its subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622),...

Company Drug

J&J’s Cetrelimab and TAR-200 Gain Tacit Approvals for Bladder Cancer Trials

Fineline Cube Oct 13, 2023

The Center for Drug Evaluation (CDE) website has indicated that Johnson & Johnson (J&J; NYSE:...

Company Medical Device

Nanjing Geneseeq’s NSCLC TMB Detection Kit Approved by NMPA

Fineline Cube Oct 13, 2023

China-based Nanjing Geneseeq Medical Device and Diagnostic Inc. has announced that its tissue tumor mutation...

Company Drug

RemeGen Secures NMPA Approval for Phase II Study of Disitamab Vedotin in Breast Cancer

Fineline Cube Oct 13, 2023

China-based biopharma RemeGen Ltd (HKG: 9995) has announced that it has received approval from the...

Company Deals

Genetron Holdings Enters Privatization Agreement with Consortium

Fineline Cube Oct 13, 2023

Beijing-based Genetron Holdings Ltd (NASDAQ: GTH) has officially entered into a privatization and merger agreement...

Company Drug

Ascentage Pharma Initiates Phase III Study for APG-2575 and Calquence in CLL/SLL

Fineline Cube Oct 13, 2023

Suzhou-based Ascentage Pharma (HKG: 6855) has announced the approval to commence a global multi-center, randomized,...

Company Drug

Betta Pharmaceuticals Secures NMPA Approval for Befotertinib in NSCLC Treatment

Fineline Cube Oct 13, 2023

China-based Betta Pharmaceuticals Co., Ltd. (SHE: 300558) has officially announced its receipt of market approval...

Company Drug

KPC Pharmaceuticals Secures WHO Prequalification for Dihydroartemisinin/Piperaquine

Fineline Cube Oct 13, 2023

Yunnan-based KPC Pharmaceuticals Inc. (SHA: 600422) has announced that its dihydroartemisinin/piperaquine 40mg/320mg formulation has received...

Company

Novartis Halts Phase II Clinical Study for MIJ821 in Major Depressive Disorder

Fineline Cube Oct 12, 2023

Novartis (NYSE: NVS), the Swiss pharmaceutical giant, has decided to hold the Phase II clinical...

Company Drug

MSD’s Keytruda Achieves Primary Endpoint in Late-Stage NSCLC Trial

Fineline Cube Oct 12, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that a late-stage trial for its...

Company

Bayer AG Plans Continued Investment in China Amidst Global Challenges

Fineline Cube Oct 12, 2023

Germany-based multinational corporation Bayer AG (ETR: BAYN) is determined to continue investing in China, as...

Company Drug

Novo Nordisk Halts Phase III Ozempic Study on Renal Impairment in Diabetes Patients

Fineline Cube Oct 12, 2023

Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has decided to discontinue a Phase III global...

Company Deals

BMS Expands CAR-T Collaboration with Cellares on Automation Tech

Fineline Cube Oct 12, 2023

Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into a technology transfer agreement with US-based Cellares,...

Posts pagination

1 … 397 398 399 … 602

Recent updates

  • Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio
  • Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal
  • Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing
  • Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China
  • BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Company Drug

Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.